The negative results from the alfaHGA study in Thailand makes Tripep refocus on ChronVac-C®

The results from the double-blind study of alphaHGA shows no significant decrease of the HIV-levels in the patients’ serum. “Naturally we are very disappointed, not least for the individuals carrying the HIV-infection. A study report will be prepared but right now it is hard to see a continuation of the alphaHGA project. We now focus our research and our resources on Hepatitis C and our candidate drug ChronVac-C®. We are well prepared and I see the following strengths in the projects: • Tripep has received a notice of allowance that the most important US patent will be reinforced today • Tripep has, through the cooperation agreement with Inovio, solved how ChronVac-C® should be given to man • In February the preclinical studies (toxicity/biodistribution etc) were initiated and they will be finalized during the autumn • The financial resources of Tripep secures the progress of the project through Phase I, estimated to start at yearend So in spite of the dismal news we have reason to feel confident of the future prospects of Tripep”, says Tripeps CEO Jan Nilsson. “Tripep is a company with several legs to stand on and I share Jan’s view of the future” says Tripeps chairman Rolf L. Nordström. For more information, please contact: Rolf L. Nordström, Chairman, Tripep AB Tel: +44 20 7839 8686, mobile phone: +44 7776 137 400 E-mail: rolf.l.nordstrom@btinternet.com Jan Nilsson, CEO, Tripep AB Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se